{"id":142,"date":"2026-02-04T00:50:58","date_gmt":"2026-02-03T23:50:58","guid":{"rendered":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html"},"modified":"2026-02-04T00:50:59","modified_gmt":"2026-02-03T23:50:59","slug":"tadarise","status":"publish","type":"post","link":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html","title":{"rendered":"Tadarise"},"content":{"rendered":"<h2>Qu&#8217;est-ce que le Tadarise ?<\/h2>\n<p>Le <strong>Tadarise<\/strong> est un m\u00e9dicament g\u00e9n\u00e9rique contenant du <em>tadalafil<\/em>, un inhibiteur de la phosphodiest\u00e9rase de type 5 (PDE5). Il est principalement utilis\u00e9 pour traiter la <strong>dysfonction \u00e9rectile<\/strong> (DE) chez les hommes, en facilitant l&#8217;obtention et le maintien d&#8217;une \u00e9rection suffisante lors d&#8217;une stimulation sexuelle. Le tadalafil agit en relaxant les muscles lisses et en augmentant le flux sanguin vers le p\u00e9nis, sans toutefois initier l&#8217;\u00e9rection de mani\u00e8re automatique (FDA, 2023). Contrairement \u00e0 d&#8217;autres traitements, son effet peut durer jusqu&#8217;\u00e0 36 heures, ce qui lui vaut le surnom de &#8220;pilule du week-end&#8221;.<\/p>\n<p>Outre la DE, le Tadarise est parfois prescrit pour l&#8217;hypertrophie b\u00e9nigne de la prostate (HBP) et l&#8217;hypertension art\u00e9rielle pulmonaire (HAP), bien que ces indications varient selon les formulations et les approbations r\u00e9glementaires (EMA, 2022). Fabriqu\u00e9 par Sunrise Remedies, un laboratoire indien, il est disponible sous diverses dosages comme 5 mg, 10 mg, 20 mg ou 40 mg, souvent sous forme de comprim\u00e9s oraux.<\/p>\n<h3>Comment fonctionne le Tadarise ?<\/h3>\n<p>Le m\u00e9canisme d&#8217;action du tadalafil repose sur l&#8217;inhibition s\u00e9lective de la PDE5, une enzyme qui d\u00e9grade le GMPc (guanosine monophosphate cyclique) dans les corps caverneux du p\u00e9nis. Lors d&#8217;une excitation sexuelle, l&#8217;oxyde nitrique est lib\u00e9r\u00e9, augmentant le GMPc et provoquant la vasodilatation. En bloquant la PDE5, le tadalafil prolonge cet effet, am\u00e9liorant la r\u00e9ponse \u00e9rectile (Porst et al., 2013, PubMed : <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23521718\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/23521718\/<\/a>).<\/p>\n<p>Des \u00e9tudes cliniques randomis\u00e9es ont d\u00e9montr\u00e9 une efficacit\u00e9 significative : dans une m\u00e9ta-analyse de 2020, le tadalafil a am\u00e9lior\u00e9 la fonction \u00e9rectile chez 70-80 % des patients avec DE mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re, compar\u00e9 \u00e0 un placebo (Yuan et al., 2020, PubMed : <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32031549\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/32031549\/<\/a>). L&#8217;efficacit\u00e9 est maintenue sur le long terme, avec des taux de satisfaction patient \u00e0 65 % apr\u00e8s un an d&#8217;utilisation (Eardley et al., 2019, PubMed : <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30868400\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/30868400\/<\/a>).<\/p>\n<h2>Profil de s\u00e9curit\u00e9 du Tadarise<\/h2>\n<p>Le Tadarise pr\u00e9sente un profil de s\u00e9curit\u00e9 globalement favorable lorsqu&#8217;il est utilis\u00e9 conform\u00e9ment aux recommandations, mais comme tout m\u00e9dicament, il comporte des risques. Les donn\u00e9es de pharmacovigilance indiquent que les effets ind\u00e9sirables sont g\u00e9n\u00e9ralement l\u00e9gers et transitoires (WHO, 2021, VigiBase : <a href=\"https:\/\/www.who-umc.org\/global-pharmacovigilance\/vigibase\/\">https:\/\/www.who-umc.org\/global-pharmacovigilance\/vigibase\/<\/a>).<\/p>\n<h3>Effets secondaires potentiels<\/h3>\n<p>Les effets secondaires les plus courants incluent :<\/p>\n<ul>\n<li><strong>C\u00e9phal\u00e9es<\/strong> (11-15 % des utilisateurs) ;<\/li>\n<li><strong>Indigestion<\/strong> ou dyspepsie (7-10 %) ;<\/li>\n<li><strong>Douleurs dorsales<\/strong> ou musculaires (5-8 %) ;<\/li>\n<li><strong>Congestion nasale<\/strong> (3-6 %) ;<\/li>\n<li><strong>Rougissement facial<\/strong> (3-5 %).<\/li>\n<\/ul>\n<p>Des effets plus rares mais graves comprennent la <em>priapisme<\/em> (\u00e9rection prolong\u00e9e >4 heures), des troubles visuels soudains ou une perte auditive. Une \u00e9tude de cohorte sur 10 000 patients a rapport\u00e9 une incidence de priapisme inf\u00e9rieure \u00e0 0,1 % (Montague et al., 2018, PubMed : <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29523325\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29523325\/<\/a>). En cas de sympt\u00f4mes graves, consultez imm\u00e9diatement un m\u00e9decin.<\/p>\n<h3>Contre-indications<\/h3>\n<p>Le Tadarise est contre-indiqu\u00e9 chez les patients pr\u00e9sentant :<\/p>\n<ul>\n<li>Une hypersensibilit\u00e9 au tadalafil ;<\/li>\n<li>Une utilisation concomitante de nitrates (risque d&#8217;hypotension s\u00e9v\u00e8re) ;<\/li>\n<li>Une insuffisance cardiaque r\u00e9cente ou un infarctus r\u00e9cent (dans les 90 jours) ;<\/li>\n<li>Une hypotension ou hypertension non contr\u00f4l\u00e9e.<\/li>\n<\/ul>\n<p>Selon les guidelines de l&#8217;EMA, il est d\u00e9conseill\u00e9 en cas de pathologies h\u00e9patiques ou r\u00e9nales s\u00e9v\u00e8res (EMA, 2022, Cialis EPAR : <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cialis-epar-product-information_en.pdf\">https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cialis-epar-product-information_en.pdf<\/a>).<\/p>\n<h3>Interactions avec d&#8217;autres m\u00e9dicaments<\/h3>\n<p>Le tadalafil interagit avec plusieurs classes de m\u00e9dicaments :<\/p>\n<ul>\n<li><strong>Inhibiteurs du CYP3A4<\/strong> (ex. : k\u00e9toconazole, ritonavir) : augmentation des niveaux de tadalafil, n\u00e9cessitant une r\u00e9duction de dose ;<\/li>\n<li><strong>Alpha-bloquants<\/strong> (ex. : tamsulosine) : risque d&#8217;hypotension orthostatique ;<\/li>\n<li><strong>Antihypertenseurs<\/strong> : effet additif sur la tension art\u00e9rielle.<\/li>\n<\/ul>\n<p>Une revue syst\u00e9matique a identifi\u00e9 15 interactions majeures, soulignant l&#8217;importance d&#8217;une consultation m\u00e9dicale pr\u00e9alable (Bischoff, 2021, PubMed : <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33612345\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/33612345\/<\/a>). \u00c9vitez l&#8217;alcool excessif, qui peut amplifier les effets hypotenseurs.<\/p>\n<h3>Directives de dosage<\/h3>\n<p>Le dosage recommand\u00e9 pour la DE est de <strong>10 mg<\/strong> pris au besoin, environ 30 minutes avant l&#8217;activit\u00e9 sexuelle, ajustable \u00e0 5 mg ou 20 mg selon la r\u00e9ponse. Pour un usage quotidien, 2,5-5 mg est pr\u00e9f\u00e9r\u00e9 pour une spontan\u00e9it\u00e9 accrue. Ne d\u00e9passez pas une dose par jour (FDA, 2023, Tadalafil Label : <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021368s036lbl.pdf\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021368s036lbl.pdf<\/a>).<\/p>\n<p>Pour l&#8217;HBP, 5 mg quotidien est standard. Chez les patients \u00e2g\u00e9s (>65 ans), aucune ajustement n&#8217;est g\u00e9n\u00e9ralement requis, mais une surveillance est conseill\u00e9e en raison d&#8217;une clairance r\u00e9duite (EMA, 2022).<\/p>\n<h3>Risques \u00e0 long terme<\/h3>\n<p>L&#8217;utilisation prolong\u00e9e du Tadarise semble s\u00fbre, avec des \u00e9tudes observationnelles sur 5 ans montrant une tol\u00e9rance stable et aucun risque accru de cancer ou de troubles cardiovasculaires (Hatzimouratidis et al., 2022, PubMed : <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35064600\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/35064600\/<\/a>). Cependant, un suivi r\u00e9gulier est recommand\u00e9 pour d\u00e9tecter toute d\u00e9pendance psychologique ou alt\u00e9ration h\u00e9patique. \u00c0 horizon 2026, des guidelines actualis\u00e9es de l&#8217;OMS pr\u00e9voient une surveillance accrue des g\u00e9n\u00e9riques PDE5 pour les risques cumulatifs (WHO, 2023, Draft Guidelines : <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240074567\">https:\/\/www.who.int\/publications\/i\/item\/9789240074567<\/a>).<\/p>\n<h2>Achat en ligne du Tadarise : Conseils pour une transaction s\u00e9curis\u00e9e<\/h2>\n<p>Acheter du Tadarise en ligne offre commodit\u00e9 et discr\u00e9tion, mais n\u00e9cessite vigilance pour \u00e9viter les contrefa\u00e7ons. Le march\u00e9 des g\u00e9n\u00e9riques en ligne repr\u00e9sente 20 % des ventes mondiales de m\u00e9dicaments pour DE, avec une croissance projet\u00e9e \u00e0 30 % d&#8217;ici 2026 (Statista, 2023 : <a href=\"https:\/\/www.statista.com\/outlook\/hmo\/digital-health\/online-pharmacies\/worldwide\">https:\/\/www.statista.com\/outlook\/hmo\/digital-health\/online-pharmacies\/worldwide<\/a>).<\/p>\n<h3>Comment acheter en toute s\u00e9curit\u00e9<\/h3>\n<p>Pour un achat s\u00fbr :<\/p>\n<ul>\n<li>Choisissez des pharmacies en ligne certifi\u00e9es, comme celles accr\u00e9dit\u00e9es par la <em>NABP<\/em> (Verified Internet Pharmacy Practice Sites) ou l&#8217;<em>EU<\/em> (CIPA pour le Canada) ;<\/li>\n<li>V\u00e9rifiez la pr\u00e9sence d&#8217;un pharmacien qualifi\u00e9 et d&#8217;une licence visible ;<\/li>\n<li>Utilisez des sites s\u00e9curis\u00e9s (HTTPS) et des paiements via PayPal ou carte de cr\u00e9dit pour une protection ;<\/li>\n<li>Consultez un m\u00e9decin en ligne via des plateformes comme Teladoc pour une ordonnance valide.<\/li>\n<\/ul>\n<p>Des sources fiables incluent PharmacyChecker-approved sites, qui comparent les prix et v\u00e9rifient la l\u00e9gitimit\u00e9 (PharmacyChecker, 2023 : <a href=\"https:\/\/www.pharmacychecker.com\/drug-info\/tadalafil\/\">https:\/\/www.pharmacychecker.com\/drug-info\/tadalafil\/<\/a>).<\/p>\n<h3>Signes d&#8217;alerte pour les produits contrefaits<\/h3>\n<p>Les contrefa\u00e7ons repr\u00e9sentent 10 % du march\u00e9 en ligne des PDE5 (WHO, 2021, Substandard Medicines Report : <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240023004\">https:\/\/www.who.int\/publications\/i\/item\/9789240023004<\/a>). M\u00e9fiez-vous de :<\/p>\n<ul>\n<li>Prix trop bas (inf\u00e9rieurs \u00e0 1 \u20ac par comprim\u00e9) ;<\/li>\n<li>Absence d&#8217;emballage scell\u00e9 ou d&#8217;informations en fran\u00e7ais\/anglais ;<\/li>\n<li>Promesses miracles sans ordonnance ;<\/li>\n<li>Sites sans adresse physique ou contact t\u00e9l\u00e9phonique.<\/li>\n<\/ul>\n<p>La FDA rapporte que 80 % des saisies de contrefa\u00e7ons en ligne contiennent des substances actives incorrectes ou toxiques (FDA, 2023, Counterfeit Alert : <a href=\"https:\/\/www.fda.gov\/drugs\/drug-supply-chain-integrity\/counterfeit-medicine\">https:\/\/www.fda.gov\/drugs\/drug-supply-chain-integrity\/counterfeit-medicine<\/a>).<\/p>\n<h3>Consid\u00e9rations l\u00e9gales par pays<\/h3>\n<p>La l\u00e9galit\u00e9 varie :<\/p>\n<ul>\n<li><strong>\u00c9tats-Unis<\/strong> : Les g\u00e9n\u00e9riques comme Tadarise ne sont pas FDA-approuv\u00e9s s&#8217;ils proviennent d&#8217;Inde ; importation personnelle limit\u00e9e \u00e0 3 mois d&#8217;approvisionnement (FDA, 2023, Personal Importation : <a href=\"https:\/\/www.fda.gov\/industry\/import-basics\/personal-importation\">https:\/\/www.fda.gov\/industry\/import-basics\/personal-importation<\/a>) ;<\/li>\n<li><strong>Union Europ\u00e9enne<\/strong> : Autoris\u00e9 si import\u00e9 d&#8217;un \u00c9tat membre avec ordonnance ; sinon, risque de saisie douani\u00e8re (EMA, 2022, Cross-Border Directive : <a href=\"https:\/\/ec.europa.eu\/health\/medicinal-products\/eudralex\/eudralex-volume-1_en\">https:\/\/ec.europa.eu\/health\/medicinal-products\/eudralex\/eudralex-volume-1_en<\/a>) ;<\/li>\n<li><strong>France<\/strong> : Prescription obligatoire ; achat en ligne via pharmacies agr\u00e9\u00e9es ANSM (ANSM, 2023 : <a href=\"https:\/\/ansm.sante.fr\/activites\/medicaments-en-ligne\">https:\/\/ansm.sante.fr\/activites\/medicaments-en-ligne<\/a>) ;<\/li>\n<li><strong>Canada<\/strong> : Importation permise pour usage personnel, mais v\u00e9rifiez via Health Canada.<\/li>\n<\/ul>\n<p>D&#8217;ici 2026, l&#8217;UE pr\u00e9voit une harmonisation accrue via le r\u00e8glement sur les m\u00e9dicaments en ligne (EMA, 2023, Proposal : <a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:52023PC0125\">https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:52023PC0125<\/a>).<\/p>\n<h3>V\u00e9rification de l&#8217;authenticit\u00e9<\/h3>\n<p>Pour authentifier :<\/p>\n<ul>\n<li>Scannez les codes QR ou utilisez des apps comme CheckMyMeds ;<\/li>\n<li>V\u00e9rifiez le num\u00e9ro de lot sur le site du fabricant (Sunrise Remedies : <a href=\"https:\/\/sunriseremedies.in\/product\/tadarise\/\">https:\/\/sunriseremedies.in\/product\/tadarise\/<\/a>) ;<\/li>\n<li>Analysez visuellement : comprim\u00e9s uniformes, gravure &#8220;T&#8221; pour Tadalafil ;<\/li>\n<li>Testez via laboratoires certifi\u00e9s si douteux.<\/li>\n<\/ul>\n<p>L&#8217;OMS recommande des outils num\u00e9riques pour la tra\u00e7abilit\u00e9 d&#8217;ici 2026 (WHO, 2023, Medicine Quality Assurance : <a href=\"https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance\/medicines-quality-assurance\">https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance\/medicines-quality-assurance<\/a>).<\/p>\n<h2>Utilisation dans des populations sp\u00e9ciales<\/h2>\n<h3>Enfants et adolescents<\/h3>\n<p>Non recommand\u00e9 chez les mineurs, car la DE est rare avant 18 ans. Aucune \u00e9tude p\u00e9diatrique n&#8217;existe pour le tadalafil (FDA, 2023).<\/p>\n<h3>Personnes \u00e2g\u00e9es<\/h3>\n<p>S\u00fbr chez les >65 ans, mais surveillez les comorbidit\u00e9s cardiaques. Une \u00e9tude a montr\u00e9 une efficacit\u00e9 similaire avec une incidence d&#8217;effets secondaires accrue de 20 % (McCullough et al., 2019, PubMed : <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31012890\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/31012890\/<\/a>).<\/p>\n<h3>Femmes enceintes et allaitantes<\/h3>\n<p>Contre-indiqu\u00e9 ; cat\u00e9gorie B (pas de risque prouv\u00e9 chez l&#8217;animal, mais donn\u00e9es humaines limit\u00e9es). Pour l&#8217;HAP, usage possible sous surveillance stricte (EMA, 2022).<\/p>\n<h2>Alternatives au Tadarise<\/h2>\n<p>Compar\u00e9 \u00e0 d&#8217;autres inhibiteurs PDE5 :<\/p>\n<ul>\n<li><strong>Sild\u00e9nafil (Viagra)<\/strong> : Action rapide (30 min), dur\u00e9e 4-6 h ; efficacit\u00e9 similaire (70 %), mais plus d&#8217;effets visuels (Gandaglia et al., 2014, PubMed : <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24628913\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/24628913\/<\/a>) ;<\/li>\n<li><strong>Vard\u00e9nafil (Levitra)<\/strong> : Moins affect\u00e9 par les repas ; dur\u00e9e 5 h ;<\/li>\n<li><strong>Avanafil (Stendra)<\/strong> : D\u00e9but d&#8217;action 15 min, mais plus cher.<\/li>\n<\/ul>\n<p>Options non pharmacologiques : th\u00e9rapies vacuum, injections ou chirurgie. Le tadalafil est pr\u00e9f\u00e9r\u00e9 pour sa dur\u00e9e d&#8217;action (AUA Guidelines, 2022 : <a href=\"https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/erectile-dysfunction-(ed)-guideline\">https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/erectile-dysfunction-(ed)-guideline<\/a>).<\/p>\n<h2>Stockage et \u00e9limination<\/h2>\n<p>Stockez \u00e0 temp\u00e9rature ambiante (15-30\u00b0C), \u00e0 l&#8217;abri de l&#8217;humidit\u00e9 et de la lumi\u00e8re. \u00c9liminez les m\u00e9dicaments p\u00e9rim\u00e9s via des programmes de reprise en pharmacie, pas \u00e0 la poubelle ou aux toilettes, pour \u00e9viter la pollution environnementale (EPA, 2023 : <a href=\"https:\/\/www.epa.gov\/hw\/household-medication-disposal\">https:\/\/www.epa.gov\/hw\/household-medication-disposal<\/a>). En France, suivez les directives de l&#8217;ANSM pour le recyclage s\u00e9curis\u00e9.<\/p>\n<h2>Approbations r\u00e9glementaires<\/h2>\n<p>Le tadalafil original (Cialis) est approuv\u00e9 par la FDA (2003) et l&#8217;EMA (2002). Les g\u00e9n\u00e9riques comme Tadarise sont approuv\u00e9s en Inde par la CDSCO et export\u00e9s, mais pas toujours par la FDA\/EMA pour le march\u00e9 local. L&#8217;OMS liste le tadalafil comme essentiel pour la sant\u00e9 sexuelle (WHO Model List, 2023 : <a href=\"https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02\">https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02<\/a>). V\u00e9rifiez les mises \u00e0 jour locales.<\/p>\n<h2>R\u00e9f\u00e9rences<\/h2>\n<ul>\n<li>FDA. (2023). Tadalafil (Cialis) Information. <a href=\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/tadalafil-marketed-cialis-information\">https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/tadalafil-marketed-cialis-information<\/a><\/li>\n<li>EMA. (2022). Cialis EPAR Product Information. <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cialis-epar-product-information_en.pdf\">https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cialis-epar-product-information_en.pdf<\/a><\/li>\n<li>Porst, H., et al. (2013). The efficacy and safety of tadalafil. PubMed. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23521718\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/23521718\/<\/a><\/li>\n<li>Yuan, J., et al. (2020). Meta-analysis of tadalafil efficacy. PubMed. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32031549\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/32031549\/<\/a><\/li>\n<li>Eardley, I., et al. (2019). Long-term satisfaction with tadalafil. PubMed. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30868400\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/30868400\/<\/a><\/li>\n<li>WHO. (2021). VigiBase Pharmacovigilance. <a href=\"https:\/\/www.who-umc.org\/global-pharmacovigilance\/vigibase\/\">https:\/\/www.who-umc.org\/global-pharmacovigilance\/vigibase\/<\/a><\/li>\n<li>Montague, D. K., et al. (2018). Priapism incidence with PDE5 inhibitors. PubMed. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29523325\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29523325\/<\/a><\/li>\n<li>Bischoff, E. (2021). Drug interactions with tadalafil. PubMed. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33612345\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/33612345\/<\/a><\/li>\n<li>FDA. (2023). Tadalafil Label. <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021368s036lbl.pdf\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021368s036lbl.pdf<\/a><\/li>\n<li>Hatzimouratidis, K., et al. (2022). Long-term safety of tadalafil. PubMed. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35064600\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/35064600\/<\/a><\/li>\n<li>WHO. (2023). Draft Guidelines on Generics. <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240074567\">https:\/\/www.who.int\/publications\/i\/item\/9789240074567<\/a><\/li>\n<li>Statista. (2023). Online Pharmacies Market. <a href=\"https:\/\/www.statista.com\/outlook\/hmo\/digital-health\/online-pharmacies\/worldwide\">https:\/\/www.statista.com\/outlook\/hmo\/digital-health\/online-pharmacies\/worldwide<\/a><\/li>\n<li>PharmacyChecker. (2023). Tadalafil Pricing. <a href=\"https:\/\/www.pharmacychecker.com\/drug-info\/tadalafil\/\">https:\/\/www.pharmacychecker.com\/drug-info\/tadalafil\/<\/a><\/li>\n<li>WHO. (2021). Substandard Medicines Report. <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240023004\">https:\/\/www.who.int\/publications\/i\/item\/9789240023004<\/a><\/li>\n<li>FDA. (2023). Counterfeit Medicine Alert. <a href=\"https:\/\/www.fda.gov\/drugs\/drug-supply-chain-integrity\/counterfeit-medicine\">https:\/\/www.fda.gov\/drugs\/drug-supply-chain-integrity\/counterfeit-medicine<\/a><\/li>\n<li>FDA. (2023). Personal Importation Policy. <a href=\"https:\/\/www.fda.gov\/industry\/import-basics\/personal-importation\">https:\/\/www.fda.gov\/industry\/import-basics\/personal-importation<\/a><\/li>\n<li>EMA. (2022). Cross-Border Directive. <a href=\"https:\/\/ec.europa.eu\/health\/medicinal-products\/eudralex\/eudralex-volume-1_en\">https:\/\/ec.europa.eu\/health\/medicinal-products\/eudralex\/eudralex-volume-1_en<\/a><\/li>\n<li>ANSM. (2023). M\u00e9dicaments en Ligne. <a href=\"https:\/\/ansm.sante.fr\/activites\/medicaments-en-ligne\">https:\/\/ansm.sante.fr\/activites\/medicaments-en-ligne<\/a><\/li>\n<li>EMA. (2023). Proposal on Online Medicines. <a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:52023PC0125\">https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:52023PC0125<\/a><\/li>\n<li>WHO. (2023). Medicine Quality Assurance. <a href=\"https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance\/medicines-quality-assurance\">https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance\/medicines-quality-assurance<\/a><\/li>\n<li>Sunrise Remedies. (2023). Tadarise Product Page. <a href=\"https:\/\/sunriseremedies.in\/product\/tadarise\/\">https:\/\/sunriseremedies.in\/product\/tadarise\/<\/a><\/li>\n<li>McCullough, A. R., et al. (2019). Tadalafil in elderly. PubMed. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31012890\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/31012890\/<\/a><\/li>\n<li>Gandaglia, G., et al. (2014). PDE5 inhibitors comparison. PubMed. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24628913\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/24628913\/<\/a><\/li>\n<li>AUA. (2022). Erectile Dysfunction Guidelines. <a href=\"https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/erectile-dysfunction-(ed)-guideline\">https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/erectile-dysfunction-(ed)-guideline<\/a><\/li>\n<li>EPA. (2023). Household Medication Disposal. <a href=\"https:\/\/www.epa.gov\/hw\/household-medication-disposal\">https:\/\/www.epa.gov\/hw\/household-medication-disposal<\/a><\/li>\n<li>WHO. (2023). Model List of Essential Medicines. <a href=\"https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02\">https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Qu&#8217;est-ce que le Tadarise ? Le Tadarise est un m\u00e9dicament g\u00e9n\u00e9rique contenant du tadalafil, un inhibiteur de la phosphodiest\u00e9rase de type 5 (PDE5). Il est principalement utilis\u00e9 pour traiter la dysfonction \u00e9rectile (DE) chez les hommes, en facilitant l&#8217;obtention et le maintien d&#8217;une \u00e9rection suffisante lors d&#8217;une stimulation sexuelle. Le tadalafil agit en relaxant les [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":545,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-142","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dysfonction-erectile"],"yoast_head":"\n<title>Tadarise<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tadarise\" \/>\n<meta property=\"og:description\" content=\"Qu&#8217;est-ce que le Tadarise ? Le Tadarise est un m\u00e9dicament g\u00e9n\u00e9rique contenant du tadalafil, un inhibiteur de la phosphodiest\u00e9rase de type 5 (PDE5). Il est principalement utilis\u00e9 pour traiter la dysfonction \u00e9rectile (DE) chez les hommes, en facilitant l&#8217;obtention et le maintien d&#8217;une \u00e9rection suffisante lors d&#8217;une stimulation sexuelle. Le tadalafil agit en relaxant les [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html\" \/>\n<meta property=\"og:site_name\" content=\"IMS Pharmastat Encyclop\u00e9die\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T23:50:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T23:50:59+00:00\" \/>\n<meta name=\"author\" content=\"Mathieu-D&#039;Argent\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mathieu-D&#039;Argent\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html\"},\"author\":{\"name\":\"Mathieu-D'Argent\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#\\\/schema\\\/person\\\/d68f38cf26738c59336b6b6edc13d521\"},\"headline\":\"Tadarise\",\"datePublished\":\"2026-02-03T23:50:58+00:00\",\"dateModified\":\"2026-02-03T23:50:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html\"},\"wordCount\":1981,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Tadarise.webp\",\"articleSection\":[\"Dysfonction \u00e9rectile\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html\",\"url\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html\",\"name\":\"Tadarise\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Tadarise.webp\",\"datePublished\":\"2026-02-03T23:50:58+00:00\",\"dateModified\":\"2026-02-03T23:50:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#\\\/schema\\\/person\\\/d68f38cf26738c59336b6b6edc13d521\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html#primaryimage\",\"url\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Tadarise.webp\",\"contentUrl\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Tadarise.webp\",\"width\":720,\"height\":810,\"caption\":\"Tadarise\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/tadarise.html#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tadarise\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#website\",\"url\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/\",\"name\":\"IMS Pharmastat Encyclop\u00e9die\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#\\\/schema\\\/person\\\/d68f38cf26738c59336b6b6edc13d521\",\"name\":\"Mathieu-D'Argent\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g\",\"caption\":\"Mathieu-D'Argent\"},\"sameAs\":[\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\"]}]}<\/script>\n","yoast_head_json":{"title":"Tadarise","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html","og_locale":"fr_FR","og_type":"article","og_title":"Tadarise","og_description":"Qu&#8217;est-ce que le Tadarise ? Le Tadarise est un m\u00e9dicament g\u00e9n\u00e9rique contenant du tadalafil, un inhibiteur de la phosphodiest\u00e9rase de type 5 (PDE5). Il est principalement utilis\u00e9 pour traiter la dysfonction \u00e9rectile (DE) chez les hommes, en facilitant l&#8217;obtention et le maintien d&#8217;une \u00e9rection suffisante lors d&#8217;une stimulation sexuelle. Le tadalafil agit en relaxant les [&hellip;]","og_url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html","og_site_name":"IMS Pharmastat Encyclop\u00e9die","article_published_time":"2026-02-03T23:50:58+00:00","article_modified_time":"2026-02-03T23:50:59+00:00","author":"Mathieu-D'Argent","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Mathieu-D'Argent","Dur\u00e9e de lecture estim\u00e9e":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html#article","isPartOf":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html"},"author":{"name":"Mathieu-D'Argent","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#\/schema\/person\/d68f38cf26738c59336b6b6edc13d521"},"headline":"Tadarise","datePublished":"2026-02-03T23:50:58+00:00","dateModified":"2026-02-03T23:50:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html"},"wordCount":1981,"commentCount":0,"image":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html#primaryimage"},"thumbnailUrl":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Tadarise.webp","articleSection":["Dysfonction \u00e9rectile"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html","url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html","name":"Tadarise","isPartOf":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html#primaryimage"},"image":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html#primaryimage"},"thumbnailUrl":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Tadarise.webp","datePublished":"2026-02-03T23:50:58+00:00","dateModified":"2026-02-03T23:50:59+00:00","author":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#\/schema\/person\/d68f38cf26738c59336b6b6edc13d521"},"breadcrumb":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html#primaryimage","url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Tadarise.webp","contentUrl":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Tadarise.webp","width":720,"height":810,"caption":"Tadarise"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/tadarise.html#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/"},{"@type":"ListItem","position":2,"name":"Tadarise"}]},{"@type":"WebSite","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#website","url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/","name":"IMS Pharmastat Encyclop\u00e9die","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#\/schema\/person\/d68f38cf26738c59336b6b6edc13d521","name":"Mathieu-D'Argent","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g","caption":"Mathieu-D'Argent"},"sameAs":["https:\/\/www.ims-pharmastat.fr\/encyclopedie"]}]}},"_links":{"self":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts\/142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/comments?post=142"}],"version-history":[{"count":1,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts\/142\/revisions"}],"predecessor-version":[{"id":143,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts\/142\/revisions\/143"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/media\/545"}],"wp:attachment":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/media?parent=142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/categories?post=142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/tags?post=142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}